WAIVER AND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT May 8, 2024Revenue Interest Purchase Agreement • August 13th, 2024 • Humacyte, Inc. • Biological products, (no disgnostic substances)
This Waiver and Amendment to Revenue Interest Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Humacyte Global, Inc., a Delaware corporation (the “Company”), Humacyte, Inc., a Delaware corporation (the “Parent” and, together with the Company, the “Obligors” and each, an “Obligor”), the Persons listed on the signature pages hereof under the heading “PURCHASERS” (each a “Purchaser” and, collectively, the “Purchasers”), and Hook SA LLC, a Delaware limited liability company (“Purchaser Agent”).
